Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy

Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy

Immunosuppressive therapy plays an important role in patients with high-risk idiopathic membranous nephropathy (IMN), but the therapeutic modality is still controversial. Methods: Corticosteroid combined with oral tacrolimus (TAC, target trough blood concentration of 4–8 ng/mL), intravenous cyclopho...

Full description

Bibliographic Details
Main Authors:	Lei Peng, Shi-Yao Wei, Lei-Ting Li, Yi-Xin He, Bing Li
Format:	Article
Language:	English
Published:	Elsevier 2016-01-01
Series:	Journal of the Formosan Medical Association
Subjects:	cyclophosphamide idiopathic membranous nephropathy mycophenolate mofetil proteinuria tacrolimus
Online Access:	http://www.sciencedirect.com/science/article/pii/S0929664615002776

Similar Items

Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population
by: Lin S, et al.
Published: (2019-07-01)

Clinical characteristics and prognosis of patients with idiopathic membranous nephropathy with kidney tubulointerstitial damage
by: Mengyao Sun, et al.
Published: (2023-12-01)

Mycophenolate mofetil versus cyclophosphamide for idiopathic membranous nephropathy; a double blind and randomized clinical trial
by: Fatemeh Hayati, et al.
Published: (2019-04-01)

Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy
by: W. Cui, et al.

A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin A nephropathy
by: Sang Youb Han, et al.
Published: (2022-07-01)

Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial
by: Aikaterini Nikolopoulou, et al.
Published: (2019-09-01)

Mycophenolate mofetil and FK506 have different effects on kidney allograft fibrosis in rats that underwent chronic allograft nephropathy
by: Luo Lei, et al.
Published: (2012-07-01)

Effect of corticosteroids combined with cyclophosphamide or mycophenolate mofetil therapy for IgA nephropathy with stage 3 or 4 chronic kidney disease: A retrospective cohort study
by: Qing Jia, et al.
Published: (2022-08-01)

Mediastinal tuberculous abscess: A rare presentation after renal transplant
by: Sukanto K Das, et al.
Published: (2019-01-01)

Two cases of idiopathic membranous nephropathy treated with rituximab
by: Jae Young Yoon, et al.
Published: (2013-09-01)

Membranous nephropathy: Treatment outline and risk stratification
by: Ziad Arabi
Published: (2012-07-01)

Pharmacogenomics of Old and New Immunosuppressive Drugs for Precision Medicine in Kidney Transplantation
by: Stefano Turolo, et al.
Published: (2023-07-01)

Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis
by: Bing Du, et al.
Published: (2017-07-01)

Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy
by: Shun-Lai Shang, et al.
Published: (2018-07-01)

Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?
by: Giuseppe Remuzzi, et al.
Published: (2010-01-01)

Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study
by: Shasha Chen, et al.
Published: (2020-02-01)

Analysis of the Clinical Effects of the Combination of Mycophenolate Mofetil with Either Tacrolimus or Cyclophosphamide
by: Xuebing Zhang, et al.
Published: (2020-11-01)

Cross-sectional analysis of immunosuppressive regimens focused on everolimus after liver transplantation in a Korean high-volume transplantation center
by: Sang-Hyun Kang, et al.
Published: (2019-12-01)

Protective effect of melatonin and mycophenolate mofetil against nephrotoxicity induced by tacrolimus in wistar rats
by: Suleyman KOC, et al.
Published: (2021-11-01)

Outcomes of Late Corticosteroid Withdrawal after Renal Transplantation in Patients Exposed to Tacrolimus and/or Mycophenolate Mofetil: Meta-Analysis of Randomized Controlled Trials
by: AK Ali, et al.
Published: (2011-10-01)

Factors affecting the long-term outcomes of idiopathic membranous nephropathy
by: Hyuk Huh, et al.
Published: (2017-03-01)

Long-Term Outcome of Patients with Lupus Nephritis: A Single Center Experience
by: Senija Rašić, et al.
Published: (2010-04-01)

Working Towards a Treat-to-Target Protocol in Juvenile Proliferative Lupus Nephritis – A Survey of Pediatric Rheumatologists and Nephrologists in Germany and Austria
by: Kristina Vollbach, et al.
Published: (2022-04-01)

Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial
by: Arun Sedhain, et al.
Published: (2018-07-01)

Current and emerging treatment options in the management of lupus
by: Jordan N, et al.
Published: (2016-03-01)

Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy
by: Xinxin Chen, et al.
Published: (2019-01-01)

Efficacy and safety of high-dose cyclophosphamide intravenous boost combined with glucocorticoid in treatment of idiopathic membranous nephropathy
by: XIE Xinfu, et al.
Published: (2021-06-01)

Successful Treatment of Mucocutaneous Lupus Erythematosus in a Dog with Prednisolone, Mycophenolate Mofetil and Tacrolimus
by: Jae-Eun Hyun, et al.
Published: (2021-04-01)

Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients
by: Mysore K. Phanish, et al.
Published: (2020-03-01)

Idiopathic multicentric Castleman disease with Sjögren’s syndrome and secondary membranous nephropathy: a case report and review of the literature
by: Yuejuan Pan, et al.
Published: (2020-12-01)

Real-World Effectiveness of Belimumab in Patients with Active Lupus
by: Yuya Sumichika, et al.
Published: (2023-12-01)

Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: treatment
by: Dorota Krasowska, et al.
Published: (2017-12-01)

New-Onset Diabetes Mellitus in Patients with Idiopathic Membranous Nephropathy Undergoing Tacrolimus and Low-Dose Corticosteroid Therapy
by: Lina Shao, et al.
Published: (2019-10-01)

Mycophenolate mofetil‐induced peripheral neuropathy in the treatment of membranous glomerulonephropathy: A case report
by: Minoo Moghimi, et al.
Published: (2021-12-01)

Sex-Specific Responses to Tacrolimus and Mycophenolate Mofetil in Spontaneously Hypertensive Rats
by: Rodrigo Oscar Marañón, et al.
Published: (2023-11-01)

Sensing Methods of Immunosuppressant Drugs: Calcineurin Inhibitors and Purine Synthesis Inhibitor Agents
by: Zahra Golsanamlou, et al.
Published: (2021-12-01)

Effects of Corticosteroid Treatment on Mycophenolic Acid Exposure in Renal Transplant Patients—Results From the SAILOR Study
by: Nima Nourbakhsh, et al.
Published: (2021-09-01)

Severe pneumonia in mycophenolate mofetil combined with low-dose corticosteroids-treated patients with immunoglobulin A nephropathy
by: Qi-Jun Wan, et al.
Published: (2015-01-01)

Comparison of the Effectiveness and Safety of Mycophenolate Mofetil and Cyclophosphamide in Lupus Nephritis: Evidence from a Real-World Study
by: Xiaohui Zhang, et al.
Published: (2023-07-01)

Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis
by: Lin W, et al.
Published: (2019-07-01)